00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
18:57 , Feb 22, 2019 |  BC Week In Review  |  Company News

SCM, Genexine purchase Argos

SCM Lifescience (Incheon, South Korea) and Genexine Inc. (KOSDAQ:095700) purchased all assets of Argos Therapeutics Inc. (Durham, N.C.) for $11.3 million and will rename the company CoImmune Inc. SCM will own 51% of CoImmune, while...
01:15 , Dec 22, 2018 |  BioCentury  |  Product Development

A year of digital progress at Novartis

Novartis AG Chief Digital Officer Bertrand Bodson is capping off his inaugural year with the pharma’s first approval of a digital therapeutic and 10 deals under his belt to integrate new technologies throughout the company....
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
04:12 , Sep 16, 2017 |  BioCentury  |  Strategy

Passing the baton

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent...
21:53 , Aug 24, 2017 |  BC Extra  |  Company News

Novartis names digital lead

Novartis AG (NYSE:NVS; SIX:NOVN) named Bertrand Bodson to the newly created position of chief digital officer effective Jan. 1, 2018. Bodson, who is chief digital and marketing officer at digital retailer Argos, which is part...
00:57 , May 19, 2017 |  BC Week In Review  |  Clinical News

FDA agrees with Argos' decision to continue Phase III of rocapuldencel-T

Argos Therapeutics Inc. (NASDAQ:ARGS) said FDA agreed with the company’s decision to continue the Phase III ADAPT trial evaluating rocapuldencel-T (AGS-003) in metastatic renal cell carcinoma (RCC) patients, despite an IDMC recommendation to discontinue the...
20:32 , Apr 21, 2017 |  BC Week In Review  |  Clinical News

Rocapuldencel-T: Additional Ph III ADAPT data

A post hoc analysis of the first 154 patients with newly diagnosed metastatic RCC enrolled in the open-label, international Phase III ADAPT trial showed that 8 intradermal injections of rocapuldencel-T over 1 year followed by...
22:27 , Apr 14, 2017 |  BC Extra  |  Company News

Management tracks

Allergy company Aimmune Therapeutics Inc. (NASDAQ:AIMT) named Eric Bjerkholt CFO. He was CFO at Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS). PureTech Health plc (LSE:PRTC) named Joan Mannick CMO of resTORbio, its aging-focused subsidiary. Mannick was executive director...
22:39 , Apr 7, 2017 |  BioCentury  |  Finance

Fade to black

At the end of 2016, investors argued that equity values had nowhere to go but up. This proved to be the case in 1Q as all market cap bands finished in the black. Sector specialists,...